Filing Flows › Companies › CorMedix › Analysis traps
CorMedix (CRMD): analysis traps
Where its figures could mislead a reader, and what to check before taking them at face value · Data: Q2 2026, to Jun 30, 2026, filed Aug 13, 2026; rules v1.1
CorMedix (CRMD): 1 rule of 10 triggered on the filings to Jun 30, 2026: stock compensation added back = no economic cost. 2 to review; 3 with insufficient data; 2 not applicable. Each is a question to verify, with the normal explanation that would produce the same figures.
Check these first
Stock compensation added back = no economic cost Triggered · severity medium · confidence high
Stock compensation was $14M, 4.4% of revenue, in FY2025; buybacks were $0 (0.0× the SBC) and the diluted share count still rose 36.4%. 'Adjusted' figures that add SBC back treat pay in shares as free; the cost is borne by every shareholder as dilution, or by the cash spent to buy the shares back.
Innocent reading: A young company paying in equity while it scales; intensity falls as revenue grows.
Receivables growing = future cash is certain To review · confidence medium
Receivables outgrew revenue in Q2 2026 (276% against 157%) and DSO is 141 against a median of 112; one quarter can be timing, so this is one to watch rather than a pattern.
Adjusted profit = economic profit To review · confidence low
Adjusted EPS was 10% or more above GAAP in 1 of the last 3 quarters: read the reconciliation before taking the adjusted figure.
Every rule
A01 FCF growth = the business improved Not triggered confidence high
Free cash flow rose $224M to $173M; working capital and lower capex explain 21% of it, so most of the gain is in operating cash flow itself.
The figures and how they are read
| Fiscal year before | FY2024 |
| Fiscal year | FY2025 |
| Operating cash flow, year before | −$51M |
| Operating cash flow | $175M |
| Capex, year before | $116K |
| Capex | $2M |
| Free cash flow, year before | −$51M |
| Free cash flow | $173M |
| Change in FCF | $224M |
| Change in capex | $2M |
| Working capital: change in its cash contribution | $47M |
| Of which: capex cut | 0.00 |
| Of which: working capital released | $47M |
| Share of the increase that need not repeat | +21.0% |
| Operating cash flow before working capital: change | 178766000.00 |
FCF = operating cash flow − cash capex; ΔFCF = ΔOCF − ΔCapEx; the working-capital part is the change in the cash-bridge items (receivables, inventory, payables, accruals), with the sign of the cash flow statement
Source: FY2025 (cash flow statement, fiscal year) · FY2024 (cash flow statement, fiscal year before)
A07 Stock compensation added back = no economic cost Triggered severity medium · confidence high
Stock compensation was $14M, 4.4% of revenue, in FY2025; buybacks were $0 (0.0× the SBC) and the diluted share count still rose 36.4%. 'Adjusted' figures that add SBC back treat pay in shares as free; the cost is borne by every shareholder as dilution, or by the cash spent to buy the shares back.
The figures and how they are read
| Fiscal year | FY2025 |
| Stock compensation | $14M |
| Revenue | $312M |
| SBC / revenue | +4.4% |
| Buybacks | 0 |
| Buybacks / SBC | 0.0 |
| Diluted shares, year before | 58,872 shares |
| Diluted shares | 80,308 shares |
| Diluted shares: change | +36.4% |
SBC / revenue from the cash flow statement's add-back; the diluted weighted share count year over year; buybacks from the financing section
Source: FY2025 (stock compensation, buybacks and the diluted share count, fiscal year)
What would explain it innocently
- A young company paying in equity while it scales; intensity falls as revenue grows
- Buybacks at prices below intrinsic value make up for the dilution over time
- A one-off grant (an acquisition, a founder award) rather than a steady level
What to look for in the filing
- The share count after the latest buybacks (the next 10-Q's cover)
- The price paid for the buybacks against the shares' value
- Unvested awards outstanding
What would show the trap does not apply
- The diluted share count falls over two years with buybacks at least equal to the stock compensation
- Stock compensation falls as a share of revenue in each of the next two years
Look again: next filing.
B02 Receivables growing = future cash is certain To review confidence medium
Receivables outgrew revenue in Q2 2026 (276% against 157%) and DSO is 141 against a median of 112; one quarter can be timing, so this is one to watch rather than a pattern.
The figures and how they are read
| Quarter | Q2 2026 |
| Revenue, year over year | +156.5% |
| Receivables, year over year | +275.9% |
| Quarter before | Q1 2026 |
| Revenue y/y, quarter before | +226.0% |
| Receivables y/y, quarter before | +183.5% |
| Days sales outstanding | 141.1 |
| DSO, median of eight quarters | 111.7 |
| Receivables | $161M |
| Revenue | $102M |
receivables and revenue against the same quarter a year earlier; DSO = receivables / quarterly revenue × days, against the median of the eight quarters before
Source: Q2 2026 (receivables and revenue) · Q2 2025 (the same quarter a year earlier)
What would show the trap does not apply
- Receivables fall back in line with revenue in the next quarter and DSO returns to its history
- The 10-Q attributes the increase to a disclosed one-off (a large customer's timing, an acquisition) and the allowance for doubtful accounts did not rise
Look again: next filing.
B08 Adjusted profit = economic profit To review confidence low
Adjusted EPS was 10% or more above GAAP in 1 of the last 3 quarters: read the reconciliation before taking the adjusted figure.
The figures and how they are read
| Quarter / adjusted EPS / GAAP EPS / gap | 2025-09-30 / 1.406 / 1.26 / 0.104; 2026-03-31 / 0.3495 / 0.43 / -0.23; 2026-06-30 / 0.29 / 0.29 / 0.0 |
| Quarters with adjusted ≥ 10% above GAAP | 1 |
| Quarters compared | 3 |
| Latest gap | +0.0% |
the analysts' 'actual' (usually the company's adjusted EPS) against GAAP net income ÷ diluted shares for the matching quarter; a gap of 10% or more counts (the stand-in until three releases' reconciliation tables are on file)
Source: 2025-09-30 (adjusted 1.41 vs GAAP 1.26) · 2026-03-31 (adjusted 0.35 vs GAAP 0.43) · 2026-06-30 (adjusted 0.29 vs GAAP 0.29)
What would show the trap does not apply
- The reconciliation shows the excluded items ending (a restructuring with its final charge, a settlement paid) and the gap to GAAP closes in the next quarters
- The excluded items are only amortisation of acquired intangibles and the cash paid for the deals is in the investing cash flow
Look again: next filing.
C02 Low net debt = no refinancing risk Insufficient data
no debt figure could be read from the balance sheet (the filing may tag it in other lines)
D03 EPS growth = profit growth Not triggered confidence high
EPS rose 2% and net income rose 31% in Q2 2026; the share count rose 28.6%: EPS growth follows profit growth.
The figures and how they are read
| Quarter | Q2 2026 |
| Quarter before | Q2 2025 |
| EPS, year before | $0.28 |
| EPS | $0.28 |
| Net income, year before | $20M |
| Net income | $26M |
| Diluted shares, year before | 71.9M shares |
| Diluted shares | 92.5M shares |
| EPS growth | +1.8% |
| Net income growth | +31.1% |
| Diluted shares: change | +28.6% |
| eps from profit | $0.09 |
| eps from share count | -$0.08 |
EPS and net income against the same quarter a year earlier; the EPS bridge attributes the change to profit first, then to the share count (the order is fixed and disclosed)
Source: Q2 2026 (net income, diluted shares, EPS) · Q2 2025 (the same quarter a year earlier)
E02 Low P/E at a cyclical peak = undervalued Insufficient data
no market value or trailing net income in the valuation research
E07 A precise DCF value = the true value Insufficient data
no DCF in the valuation research for this company
J06 A bank's low P/E and high profit = safe Not applicable
not a bank
J08 A REIT's low net income = the dividend is unsafe Not applicable
not a REIT
What the statuses mean
Triggered: the filings show the pattern; read the normal explanations and the missing evidence before concluding anything. To review: one quarter or a weak signal; a reader's judgement, not a pattern. Not triggered: the pattern is absent on these figures. Insufficient data: the filings read so far do not hold what the rule needs; this is not a clean bill. Not applicable: the rule is not meant for this kind of company (a bank's working capital, a loss-making quarter's EPS growth). Out of date: the latest filing is more than fifteen months old.
Severity is what the pattern could mean for cash, value or solvency; confidence is how reliable the inputs and the reading are. The two are kept apart.
Record a view
A reader's judgement, grounds, what would change it and the next review; kept in the browser (needs JavaScript).
Every rule and the companies it triggers on → CorMedix: cash flow →
Each rule reads the company's own filings by a fixed formula and says what would explain the same figures innocently. A triggered rule is a question to verify, not a finding of manipulation, and not a view on the stock. Missing data is shown as missing, never as clear. Not investment advice.